title: Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?
authors.forename: B E
authors.initials: BE
authors.lastname: Joven
authors.forename: R
authors.initials: R
authors.lastname: Almodóvar
authors.forename: M
authors.initials: M
authors.lastname: Galindo
authors.forename: I
authors.initials: I
authors.lastname: Mateo
authors.forename: J L
authors.initials: JL
authors.lastname: Pablos
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001168:Arthritis / Q000188:drug therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D007111:Immunity, Cellular / Q000187:drug effects; D000069285:Infliximab; D008875:Middle Aged; D009894:Opportunistic Infections / Q000517:prevention & control; D011446:Prospective Studies; D014374:Tuberculin Test; D014376:Tuberculosis / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab